Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis
© 2017 Elsevier Ltd Background Fibrinolytic therapy offers an alternative to mechanical reperfusion for ST-segment elevation myocardial infarction (STEMI) in settings where health-care resources are scarce. Comprehensive evidence comparing different agents is still unavailable. In this study, we exa...
Saved in:
Main Authors: | Jinatongthai P., Kongwatcharapong J., Foo C., Phrommintikul A., Nathisuwan S., Thakkinstian A., Reid C., Chaiyakunapruk N. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027506306&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40165 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis
by: Peerawat Jinatongthai, et al.
Published: (2018) -
Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis
by: Peerawat Jinatongthai, et al.
Published: (2018) -
Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand
by: Krittimeth Trerayapiwat, et al.
Published: (2022) -
Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction
by: Bøtker, H.E., et al.
Published: (2021) -
Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand
by: Trerayapiwat K.
Published: (2023)